Skip to content
Buy This GLP
← Research
Evidence

Does Tirzepatide Help Sleep Apnea? What Two Trials Found

Tirzepatide reduced breathing interruptions by 20 to 24 events an hour more than placebo in two trials of adults with obesity and moderate-to-severe obstructive sleep apnea.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team5 min read
Fewer events per hour vs placebo at week 52 (95% CI)Trial 1 · People not using PAP20.0 (14.2–25.8)Trial 2 · People enrolled on PAP23.8 (17.9–29.6)

The FDA approved Zepbound (tirzepatide) to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside a reduced-calorie diet and increased physical activity [4]. The evidence below applies to this drug and population.

What the trials found at 52 weeks

The two SURMOUNT-OSA trials compared tirzepatide with placebo. Trial 1 enrolled people who were unable or unwilling to use positive airway pressure (PAP). Trial 2 enrolled people already on PAP. They continued PAP during the trial, with a seven-day pause before assessment of the primary outcome. Participants in both groups received diet and physical activity counseling [1] [4].

The apnea-hypopnea index (AHI) counts episodes of stopped or reduced breathing per hour of sleep. Mean baseline AHI across the treatment and placebo groups was 51.5 in Trial 1 and 49.5 in Trial 2. At week 52, estimated AHI changes in Trial 1 were −25.3 with tirzepatide and −5.3 with placebo, a difference of −20.0 events per hour (95% confidence interval −25.8 to −14.2). In Trial 2, changes were −29.3 and −5.5, a difference of −23.8 (−29.6 to −17.9). Both comparisons had P < 0.001 [1].

In a separate analysis, a UK study of new sleep apnea diagnoses found no clear reduction in incident OSA among adults with obesity and type 2 diabetes who started a GLP-1 receptor agonist compared with those who started a DPP-4 inhibitor. That study asked about prevention, while SURMOUNT-OSA measured changes in adults who already had OSA [2].

Dose and coverage

The trials began at 2.5 mg weekly and took up to 20 weeks to reach the maximum tolerated dose of 10 or 15 mg. Those are also the approved weekly maintenance doses for OSA [4]. If comparing self-pay offers, check how quoted prices change with dose before using a starting price to estimate ongoing costs.

The Medicare guide to Zepbound for OSA explains how the diagnosis, supporting records and plan rules affect coverage. Published cash prices may apply to different formulations or care packages, so check what the price includes.

Follow-up for people who use PAP

A survey of 24 European sleep centers found that PAP management and follow-up practices varied. It describes what centers reported, without measuring individual patient outcomes [3].

The American Academy of Sleep Medicine says follow-up polysomnography or home sleep apnea testing may be appropriate after a clinically significant weight change [5].

Frequently asked

Is tirzepatide approved for sleep apnea?
The FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.
What dose did the sleep apnea trials use?
The trials began at 2.5 mg weekly and increased the dose over up to 20 weeks to the maximum tolerated dose of 10 or 15 mg weekly. Each trial lasted 52 weeks.
How can I tell whether my sleep apnea has improved?
A sleep clinician can assess your symptoms and decide whether to repeat a laboratory sleep study or use a home sleep apnea test. The trials used polysomnography to measure the apnea-hypopnea index.
Does tirzepatide replace PAP therapy?
The trials did not test permanent PAP withdrawal. Participants who enrolled on PAP paused it before the main outcome assessment. Consult your sleep clinician before changing or stopping PAP therapy.

Sources

  1. [1] Malhotra A, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. PMID 38912654
  2. [2] Khouri C, et al. (2026). Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study American Journal of Respiratory and Critical Care Medicine. PMID 42745463
  3. [3] Testelmans D, Bonsignore MR, Pataka A, Fanfulla F, et al. (2026). Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network Pulmonology. PMID 42639925
  4. [4] U.S. Food and Drug Administration (2026). Zepbound (tirzepatide) U.S. prescribing information FDA. Source
  5. [5] Caples SM, et al. (2021). Use of polysomnography and home sleep apnea tests for the longitudinal management of obstructive sleep apnea in adults: an American Academy of Sleep Medicine clinical guidance statement Journal of Clinical Sleep Medicine. PMID 33704050

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence